Low testosterone tracks with higher cancer mortality in long-term male cohorts
Men with very low testosterone levels faced a higher risk of dying from cancer later in life in a large international analysis that pooled data from more than 26,000 participants across 11 long-running studies. The excess risk was measured at 18% for cancer death among men in the lowest fifth of testosterone levels compared with those in the highest fifth. The signal was not uniform across cancer types, and it was not a simple story of testosterone driving prostate cancer biology.
A threshold also emerged. Once baseline testosterone fell below 8.6 nmol/L, future cancer risk began to rise. Healthy younger men typically sit in a broader range of about 10 to 30 nmol/L, with levels tending to decline with age. Low testosterone may therefore function less as a diagnosis in itself and more as an accessible marker of underlying vulnerability.
What the hormone data actually showed
The analysis drew on blood samples collected years earlier and linked them to later cancer diagnoses and cancer deaths. Investigators examined testosterone, dihydrotestosterone, sex hormone-binding globulin, and luteinizing hormone, then compared those hormone concentrations with outcomes recorded over subsequent decades. This design matters because it places hormone measurements well before the cancer endpoints, making the association harder to dismiss as a consequence of undetected advanced disease alone.
The pattern for testosterone was straightforward in one respect and surprising in another. Lower levels were tied to a higher risk of cancer death overall, yet natural testosterone concentration was not associated with prostate cancer risk. In a field where testosterone is often discussed in the same breath as prostate disease, that separation is clinically important. It suggests that the endocrine environment linked to prostate carcinogenesis is more complex than testosterone alone.
Low testosterone did not behave as a universal cancer trigger. It behaved more like an indicator of men who may be less resilient when serious disease appears years later.
Why prostate cancer followed a different hormonal pattern
Prostate cancer is often framed through the lens of androgen dependence because testosterone suppression remains a standard treatment in advanced disease. But this study found no evidence that a man’s naturally occurring testosterone concentration predicted whether he would develop prostate cancer. Instead, prostate cancer risk was more closely linked to lower levels of sex hormone-binding globulin and luteinizing hormone.
That split matters biologically. Luteinizing hormone, produced by the pituitary gland, drives the testes to make testosterone, while SHBG regulates the amount of circulating hormone that is bioavailable to tissues. Shifts in those upstream regulators may reflect broader disturbances in endocrine signaling, metabolic health, or age-related physiological change. In other words, prostate cancer risk may be tied not to total testosterone alone, but to the regulatory network that governs sex steroid balance.
Why a low testosterone result may deserve a broader workup
The practical bedside implication is not that men should start testosterone to ward off cancer. No such preventive effect was shown, and the data do not support testosterone supplementation as a cancer-prevention strategy. The stronger message is that unexpectedly low testosterone may justify a more complete medical evaluation.
Low testosterone can be influenced by body mass index, physical activity, and medical conditions such as diabetes. A low value may point to cardiometabolic disease, chronic illness, poor overall health, or other risk factors that were already in motion long before any cancer diagnosis. In that sense, the hormone result could function as an early warning light rather than the cause of the problem itself.
A biomarker, not a treatment target
The study does not establish causation. Association alone cannot prove that low testosterone leads to cancer death, and it cannot show that correcting the hormone level would lower risk. That distinction is essential for clinicians who might otherwise be tempted to translate an observational signal into a treatment decision.
Still, the findings give testosterone a new place in risk assessment discussions. A man found to have low testosterone for any reason should not be told only that the number is below normal. He should also be assessed for the broader health context in which that number appeared. A focused review of metabolic status, activity patterns, body composition, and other conditions may reveal problems worth addressing before cancer ever enters the picture.
How the cohort was assembled and why it carries weight
The study came from the Androgens In Men Study, an international collaboration led by Professor Bu Yeap at the University of Western Australia. Published in The Lancet Healthy Longevity, it pulled together individual participant data from men enrolled in Australia, the United States, and Europe. That scale strengthens the findings because it reduces reliance on a single population or a single laboratory platform.
The long follow-up is equally important. Cancer outcomes collected over decades give the hormone measurements time to show whether they carry prognostic value. For a marker like testosterone, which changes with age and comorbidity, long-term observation is more informative than a short snapshot.
The study also reinforces a familiar but sometimes underappreciated point in male health: hormones are signals, not isolated facts. A low testosterone level may reflect the body’s broader state far more than it explains a future cancer diagnosis. Clinicians looking at this result should think beyond replacement therapy and toward whole-patient assessment, especially when the level falls below 8.6 nmol/L.
The unresolved question is not whether testosterone should be prescribed more often. It is whether an unexpectedly low result can help identify men who need closer surveillance for other health threats long before cancer becomes clinically visible.